Prognostic variables and survival in pediatric acute lymphoblastic leukemias: Cancer Institute experience

Pediatric Hematology and Oncology

Volumn 13, Issue 3, 1996, Pages 205-216

  Shanta, V ^a   Maitreyan, V ^a   Sagar, T G ^a   Gajalakshmi, C K ^a   Rajalekshmy, K R ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

acute lymphoblastic leukemia; complete remission; event free survival; prognostic variables; relapse free survival

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN PROTECTION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIA; INFECTION SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL DRUG ADMINISTRATION; PROGNOSIS; RISK ASSESSMENT;

EID: 0029868567     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019609030819     Document Type: Article

References (24)

1. Miller DR, Sonley M, Karon M, et al. Additive therapy in the maintenance of remission in acute lymphoblastic leukemia of childhood: The effect of the initial leukocyte count. Cancer. 1974; 34:508-517.
2. George S, Fernback K, Vietti T, et al. Factors influencing survival in acute leukemia. Cancer. 1973;32:1542-53.
3. Simone J. Factors that influence hematological remission duration in acute lymphocytic leukemia. Br J Haematol. 1976;32:465-472.
4. Zippin C, Cutler S, Reeves W, et al. Variation in survival among patients with acute lymphoblastic leukemia. Blood. 1971;37:59-72.
5. Sather H. Age at diagnosis in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:166-172.
6. Henze G, Langermann H, Kauffman U, et al. Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1981;3:369-376.
7. Robinson L, Sather H, Coccia PF, et al. Assessment of the interrelationship of prognostic factors in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1980;2:5-13.
8. Miller DR. Acute lymphoblastic leukemia. Pediatr Clin North Am. 1980;27:269-291.
9. Steinhorn SC. Improved survival among children with acute leukemia diagnosed in 1990. Cancer Treat Rep. 1984;68:953-958.
10. Miller DR, Leikin S, Albo V, et al. Prognostic importance of morphology (FAB classification) in childhood ALL. Br Jr Haematol. 1981;48:199-206.
11. Bennet JM, Catovskey D, Daniel MT, et al. French American Co-op Group: The morphological classification of acute lymphoblastic leukemia - Concordance among observers & clinical correlation. Br Jr Haematol. 1981;47:553-556.
12. Hammond D, Sather H, Nesbit M, et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:124.
13. Miller DR, Coccia PF, Bleyer WA, et al. FAB morphology and early response to induction therapy in childhood acute lymphoblastic leukemia. Blood. 1987;70(Suppl):235a.
14. Poplack DG. Acute lymphoblastic leukemia in childhood. Pediatr Clin North Am. 1985;32:669-697.
15. Coccia PF, Bleyer WA, Siegal SE, et al. Development of preliminary findings of Children's Cancer Study Group protocols (161, 162 & 163) for low-average and high risk acute lymphoblastic leukemia in children. In: Murphy SB, Gilbert JR eds. Leukemia Research: Advances in Cell Biology & Treatment. New York: Elsevier Science; 1983:241-250.
16. Greaves MF, Janossy G, Peto J, et al. Immunologically defined subclasses of acute leukemia in children: Their relationship to presentation features and prognosis. Br J Haematol. 1981;48:179.
17. Sallan SE, Ritz J, Pesando J, et al. Cell surface antigens and prognostic implication in children with acute lymphoblastic leukemia. Blood. 1980;55:395-402.
18. Pullen DJ, Boyett JM, Crist W, et al. Pediatric oncology group: Utilisation of immunologic markers in the designation of acute lymphoblastic leukemia subgroup - Influence on treatment response. Ann NY Acad Sci. 1984;428:26-48.
19. Borowitz MJ. Immunologic markers in childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 1990;4(4):743-765.
20. Greaves MF. Subtypes of acute lymphoblastic leukemia: Implications for pathogenesis and epidemiology of leukemia. In: Magrath I, O'Conor GT, Ramot B, eds. Pathogenesis of Leukemia and Lymphomas - Environmental Influences. New York: Raven Press; 1984;27:129-139.
21. Eden OB, Lilleyman J, Shaw MP, et al. Medical Research Council Childhood Leukemia Trial VIII compared with Trials II-VII: Lessons for future management. In: Hematology & Blood Transfusion, Vol. 30, Buchner T, Schellong G, Hiddemann W, et al., eds. Acute Leukemias. Berlin: Springer Verlag; 1987;30:448-452.
22. Miller DR, Leiken S, Vincent Albo, et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood CCG 141 - A report from CCSF. Cancer. 1983;51:1041-1049.
23. Henze G, Langermann HS, Ritter J, et al. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia - A report from the BFM study group. In: Haematology & Blood Transfusion, Vol. 26. Neth, Gallo, Greq, et al., eds. Modern Trends in Human Leukemia IV, Berlin: Springer Verlag; 1981;26:87-93.
24. Kalwinsky DK, Rivera G, Dahl GV, et al. Variations by race in presenting clinical and biologic features of childhood acute lymphoblastic leukemia - Implications for treatment outcome. Leuk Res. 1985;9:817-823.